Evidence map›Paper›PMID 36294940›Full record

ArticleLife (Basel, Switzerland)2022

MND Phenotypes Differentiation: The Role of Multimodal Characterization at the Time of Diagnosis.

Giuseppe Meo, Pilar M Ferraro, Marta Cillerai, Chiara Gemelli, Corrado Cabona, Federico Zaottini, Luca Roccatagliata, Flavio Villani, Angelo Schenone, Claudia Caponnetto

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giuseppe MeoDepartment of Neurology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Pilar M FerraroDepartment of Neurology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0002-5008-2791
Marta CilleraiDepartment of Neurology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Chiara GemelliDepartment of Neurology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0003-1911-2726
Corrado CabonaDivision of Clinical Neurophysiology and Epilepsy Center, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Federico ZaottiniDepartment of Radiology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Luca RoccatagliataDepartment of Neuroradiology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Flavio VillaniDivision of Clinical Neurophysiology and Epilepsy Center, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0002-2762-4599
Angelo SchenoneDepartment of Neurology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0002-2604-7830
Claudia CaponnettoDepartment of Neurology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Funding

Italian Ministry of Health 5×1000 2016Italian Ministry of Health NET-2018-12366666
6 · The paper itself

Abstract

Pure/predominant upper motor neuron (pUMN) and lower motor neuron (pLMN) diseases have significantly better prognosis compared to amyotrophic lateral sclerosis (ALS), but their early differentiation is often challenging. We therefore tested whether a multimodal characterization approach embedding clinical, cognitive/behavioral, genetic, and neurophysiological data may improve the differentiation of pUMN and pLMN from ALS already by the time of diagnosis. Dunn’s and chi-squared tests were used to compare data from 41 ALS, 34 pLMN, and 19 pUMN cases with diagnoses confirmed throughout a 2-year observation period. Area under the curve (AUC) analyses were implemented to identify the finest tools for phenotypes discrimination. Relative to ALS, pLMN showed greater lower limbs weakness, lower UMN burden, and progression rate (p < 0.001−0.04). PUMN showed a greater frequency of lower limbs onset, higher UMN burden, lower ALSFRS-r and MRC progression rates (p < 0.001−0.03), and greater ulnar compound muscle action potential (CMAP) amplitude and tibial central motor conduction time (CMCT) (p = 0.05−0.03). The UMN progression rate was the finest measure to identify pLMN cases (AUC = 90%), while the MRC progression rate was the finest tool to identify pUMN (AUC = 82%). Detailed clinical and neurophysiological examinations may significantly improve MNDs differentiation, facilitating prognosis estimation and ameliorating stratification strategies for clinical trials enrollment.

Indexed as

amyotrophic lateral sclerosisdifferential diagnosismotor neuron diseasesmultimodal characterization

Identifiers

PMID36294940
PMCPMC9604895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.